- Home
- MNY vs MCRB Comparison
MNY vs MCRB Comparison
Compare MNY & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNY | MCRB |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 47.4M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MNY | MCRB |
|---|---|---|
| Price | $0.92 | $4.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $14.00 |
| AVG Volume (30 Days) | 11.1K | ★ 55.1K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $4.46 |
| 52 Week High | $2.40 | $29.98 |
Technical Indicators
Market Signals| Indicator | MNY | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 35.46 |
| Support Level | $0.78 | N/A |
| Resistance Level | $1.03 | $5.65 |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 7.44 |
Price Performance
Historical ComparisonAbout MNY MoneyHero Limited
MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.